2015
Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics
Black JD, Altwerger GH, Ratner E, Lu L, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics. Gynecologic And Obstetric Investigation 2015, 81: 169-173. PMID: 26067608, DOI: 10.1159/000431219.Peer-Reviewed Original ResearchMucinous tumorsSeromucinous tumorsOvarian tumorsComplete surgical stagingNormal-appearing appendixBorderline ovarian tumorsLymph node involvementRetrospective cohort analysisRisk of recurrenceAggressive stagingNodal diseaseSurgical stagingHazard ratioNode involvementDisease recurrencePseudomyxoma peritoneiSerous tumorsSingle institutionPathology reportsCohort analysisLower riskRecurrenceMultivariate analysisFrozen sectionsTumors
2012
Prognostic factors and treatment-related outcomes in patients with uterine serous cancer (USC).
deLeon M, Lu L, Hui P, Santin A, Rutherford T, Arin-Silasi D, Azodi M, Ratner E, Schwartz P. Prognostic factors and treatment-related outcomes in patients with uterine serous cancer (USC). Journal Of Clinical Oncology 2012, 30: 5099-5099. DOI: 10.1200/jco.2012.30.15_suppl.5099.Peer-Reviewed Original ResearchStage IA/IBDisease-free survivalUterine serous cancerIIIA/IIIBIVA/IVBIA/IBUSC patientsPrognostic factorsMyometrial invasionLargest single-institution experienceWhole-pelvis radiation therapyLymph node involvementPlatinum-based chemotherapySingle institution experienceIndependent prognostic factorLymph node metastasisTreatment-related outcomesUterine cancer deathsBetter OSII-IVBIB diseaseNode involvementSurgical debulkingSerous cancerShorter OS
2008
High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1
Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Research And Treatment 2008, 117: 131-140. PMID: 18932017, DOI: 10.1007/s10549-008-0219-7.Peer-Reviewed Original ResearchConceptsMiR-21 expressionPoor disease-free survivalHigh miR-21 expressionDisease-free survivalHormone receptor statusHigh miR-21Breast cancerMiR-21Tumor samplesReceptor statusTumor gradeTGF-β1Elevated miR-21 expressionNegative hormone receptor statusProportional hazards regression analysisHigher TGF-β1Lymph node involvementEarly-stage diseaseEarly-stage patientsPrimary breast cancerHazards regression analysisHigh tumor gradeFresh tumor samplesTumor cell growthNode involvement